INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR EXUDATIVE RETINAL ARTERIAL MACROANEURYSMS.

Abstract

PURPOSE:

There is no established therapy for exudative-hemorrhagic complications in primary retinal arteriolar macroaneurysm (RAM).

METHODS:

Retrospective multicenter interventional study of anti-vascular endothelial growth factor in symptomatic RAMs. Central macular thickness in μm and best-corrected visual acuity in logMar were correlated with the RAM size and distance to the macula. Statistical analyses were performed using paired comparisons and Pearson correlation.

RESULTS:

Thirty-two eyes (32 patients) were treated with a mean of 2.7 injections over a mean follow-up of 16.6 months. Initial best-corrected visual acuity correlated with the RAM size and distance to the macula (P = 0.02). Central macular thickness decreased by 131,180, and 211 μm at 1, 2, and 3 months after the first injection (P < 0.001). Best-corrected visual acuity improved by 0.47 and 0.38 Early Treatment Diabetic Retinopathy Study lines at 2 and 3 months (P = 0.005). Anti-vascular endothelial growth factor response correlated with the RAM size (P = 0.04) and the distance to the macula (P = 0.009).

CONCLUSION:

Symptomatic RAMs can be treated successfully with anti-vascular endothelial growth factor injections, leading to a decrease in macular edema.

• Authors: Ahmad M Mansour, Robert E Foster, Roberto Gallego-Pinazo, Marilita M Moschos, Robert A Sisk, Jay Chhablani, Duangnate Rojanaporn, Tharikarn Sujirakul, J Fernando Arevalo, Luiz H Lima, Lihteh Wu, Abdulrazzak Charbaji, Ali O Saatci, Hana A Mansour, Clara Martinez-Rubio, Yogin Patel, Sankeert Gangakhedkar
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 39 Issue 6 Pg. 1133-1141 (Jun 2019) ISSN: 1539-2864 [Electronic] United States
• PMID: 29505440 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Angiogenesis Inhibitors
• Recombinant Fusion Proteins
• aflibercept
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor
• Ranibizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Drug Therapy, Combination
• Exudates and Transudates
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Intravitreal Injections
• Macula Lutea (pathology)
• Ranibizumab (administration & dosage)
• Receptors, Vascular Endothelial Growth Factor (administration & dosage, antagonists & inhibitors)
• Recombinant Fusion Proteins (administration & dosage)
• Retinal Arterial Macroaneurysm (diagnosis, drug therapy)
• Retrospective Studies
• Tomography, Optical Coherence
• Treatment Outcome
• Visual Acuity